Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
99,963,154
-
Total 13F shares
-
98,821,219
-
Share change
-
+3,693,430
-
Total reported value
-
$12,420,453,326
-
Put/Call ratio
-
74%
-
Price per share
-
$125.69
-
Number of holders
-
578
-
Value change
-
+$494,184,481
-
Number of buys
-
295
-
Number of sells
-
286
Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) as of Q2 2025
As of 30 Jun 2025,
NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) was held by
578 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
98,821,219 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Dodge & Cox, STATE STREET CORP, JPMORGAN CHASE & CO, PRICE T ROWE ASSOCIATES INC /MD/, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
581
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.